Ashok Gnxt Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-12-2024
- Paid Up Capital ₹ 0.10 M
as on 16-12-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.50 M
as on 16-12-2024
- Satisfied Charges ₹ 1.65 Cr
as on 16-12-2024
- Revenue -10.71%
(FY 2023)
- Profit -290.13%
(FY 2023)
- Ebitda -2291.43%
(FY 2023)
- Net Worth -553.24%
(FY 2023)
- Total Assets 21.53%
(FY 2023)
About Ashok Gnxt Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.50 M. The company has closed loans amounting to ₹1.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
Samir Shah, Mahesh Shah, Rohan Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909GJ2019PTC107421
- Company No.
107421
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Apr 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ashok Gnxt Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohan Shah  | Director | 26-Oct-2021 | Current |
| Samir Shah | Director | 26-Oct-2021 | Current |
| Mahesh Shah | Director | 26-Oct-2021 | Current |
Eishi Maekawa  | Director | 26-Oct-2021 | Current |
Financial of Ashok Gnxt Pharma.
Ashok Gnxt Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.71% decrease. The company also saw a substantial fall in profitability, with a 290.13% decrease in profit. The company's net worth observed a substantial decline by a decrease of 553.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ashok Gnxt Pharma?
In 2023, Ashok Gnxt Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Skites Pharma Private LimitedActive 7 years 9 monthsSamir Shah, Mahesh Shah and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Jun 2022 | ₹3.50 M | Open |
Hdfc Bank Limited Creation Date: 07 Jun 2019 | ₹1.65 Cr | Satisfied |
How Many Employees Work at Ashok Gnxt Pharma?
Ashok Gnxt Pharma has a workforce of 43 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ashok Gnxt Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ashok Gnxt Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
